Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 3
Abstract
Application of “omics” technology during drug discovery and development is rapidly evolving. This review evaluates the current status and future role of “metabonomics” as a tool in the drug development process to reduce the safety-related attrition rates and bridge the gaps between preclinical and clinical, and clinical and market. Particularly, the review looks at the knowledge gap between the pharmaceutical industry and pediatric hospitals, where metabonomics has been successfully applied to screen and treat newborn babies with inborn errors of metabolism. An attempt has been made to relate the clinical pathology associated with inborn errors of metabolism with those of drug-induced pathology. It is proposed that extending the metabonomic biomarkers used in pediatric hospitals, as “advanced clinical chemistry” for preclinical and clinical drug development, is immediately warranted for better safety assessment of drug candidates. The latest advances in mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy should help replace the traditional approaches of laboratory clinical chemistry and move the safety evaluation of drug candidates into the new millennium.
Authors and Affiliations
Subrahmanyam Vangala, Alfred Tonelli
Keywords
Related Articles
- EP ID EP681599
- DOI 10.1208/aapsj0903031
- Views 101
- Downloads 0
Characterization of the humanMDR1 gene
P-glycoprotein (Pgp), an ATP-dependent efflux transporter that protects the body from environmental toxins and xenobiotics, is encoded by the humanMDR1 gene. HumanMDR1 is located on chromosomal region 7q21. Although seve...
The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data
A significant bias in parameters, estimated with the proportional odds model using the software NONMEM, has been reported. Typically, this bias occurs with ordered categorical data, when most of the observations are foun...
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
An overview is provided of the present population analysis methods and an assessment of which software packages are most appropriate for various PK/PD modeling problems. Four PK/PD example problems were solved using the...
In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands
The use of combinatorial libraries for the identification of novel opiate and related ligands in opioid receptor assays is reviewed. Case studies involving opioid assays used to demonstrate the viability of combinatorial...
Paradigm Shift in Toxicity Testing and Modeling
The limitations of traditional toxicity testing characterized by high-cost animal models with low-throughput readouts, inconsistent responses, ethical issues, and extrapolability to humans call for alternative strategies...